Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

100 trials found

Recruiting 950,000 target

Maternal Newborn Health Registry

NICHD Global Network for Women's and Children's Health

NCT01073475

Recruiting 150,000 target

Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs

Children's Hospital of Philadelphia

NCT02493478

Recruiting 100,000 target

Product Surveillance Registry

Medtronic

NCT01524276

Recruiting 100,000 target

Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility

St. Jude Children's Research Hospital

NCT01354002

Recruiting 100,000 target

US National OCS Liver Perfusion (OLP) Registry

TransMedics

NCT05940857

Recruiting 100,000 target

Caris Biorepository Research Protocol

Caris Science

NCT01499394

Recruiting NA 100,000 target

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

University of California, San Francisco

NCT02620852

Recruiting 100,000 target

International Weight Control Registry

Tufts University

NCT04907396

Recruiting 99,999 target

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Center for International Blood and Marrow Transplant Research

NCT01351545

Recruiting 80,000 target

Generic Database of Very Low Birth Weight Infants

NICHD Neonatal Research Network

NCT00063063

Recruiting 75,000 target

Project: Every Child for Younger Patients With Cancer

Children's Oncology Group

NCT02402244

Recruiting 68,000 target

Follow-up Visit of High Risk Infants

NICHD Neonatal Research Network

NCT00009633

Recruiting 50,000 target

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio

NCT03452774

Recruiting 50,000 target

Childhood Cancer Survivor Study

St. Jude Children's Research Hospital

NCT01120353

Recruiting 40,000 target

Stroke Thrombectomy and Aneurysm Registry

Medical University of South Carolina

NCT04994756

Recruiting NA 36,503 target

Supraglottic Airway for Resuscitation Trial

Children's Hospital of Philadelphia

NCT07150923

Recruiting 35,000 target

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

CHDI Foundation

NCT01574053

Recruiting Phase 3 32,000 target

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

Pfizer

NCT07282665

Recruiting 30,000 target

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Agendia

NCT03053193

Recruiting Phase 4 30,000 target

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

ModernaTX

NCT07266558

Recruiting Phase 3 25,500 target

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

BioNTech SE

NCT07300839

Recruiting 25,000 target

Parkinson's Foundation PD GENEration Genetic Registry

Parkinson's Foundation

NCT04994015

Recruiting Phase 4 20,000 target

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

Duke University

NCT04262206

Recruiting 20,000 target

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

Duke University

NCT02418442

Recruiting 20,000 target

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

Medtronic

NCT00271180

Recruiting 20,000 target

Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network

National Human Genome Research Institute (NHGRI)

NCT02450851

Recruiting Phase 3 15,100 target

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

AstraZeneca

NCT07000357

Recruiting 15,000 target

Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation

Heart Rhythm Clinical and Research Solutions

NCT04088071

Recruiting NA 14,400 target

The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now

Boston Children's Hospital

NCT05591066

Recruiting Phase 3 12,800 target

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Amgen

NCT07037433

Recruiting Phase 3 11,800 target

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Boehringer Ingelheim

NCT07064473

Recruiting Phase 3 11,300 target

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

AstraZeneca

NCT06677060

Recruiting Phase 3 11,000 target

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Alnylam Pharmaceuticals

NCT07181109

Recruiting Phase 3 11,000 target

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

Amgen

NCT07136012

Recruiting Phase 3 11,000 target

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Boehringer Ingelheim

NCT06531824

Recruiting Phase 4 10,742 target

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

Ohio State University

NCT06468202

Recruiting 10,000 target

Collection and Distribution of Biospecimens for Novel Research Uses

iSpecimen

NCT03848962

Recruiting 10,000 target

Comprehensive HHT Outcomes Registry of the United States (CHORUS)

Cure HHT

NCT06259292

Recruiting 10,000 target

Tracking Results of Ablations to Combat AF Registry Generation 2

AtriCure

NCT05111015

Recruiting Phase 2 10,000 target

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

SWOG Cancer Research Network

NCT03851445

Recruiting Phase 2 10,000 target

A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

Eli Lilly and Company

NCT05986292

Recruiting Phase 3 10,000 target

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

Novo Nordisk A/S

NCT06118281

Recruiting Phase 2 9,999 target

Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

New York Blood Center

NCT01656603

Recruiting 9,000 target

Fabry Disease Registry & Pregnancy Sub-registry

Genzyme, a Sanofi Company

NCT00196742

Recruiting NA 8,946 target

Colonoscopy vs Stool Testing for Older Adults With Colon Polyps

Dartmouth-Hitchcock Medical Center

NCT05612347

Recruiting Phase 4 8,600 target

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Currax Pharmaceuticals

NCT06098079

Recruiting NA 8,000 target

Nutrition for Precision Health, Powered by the All of Us

RTI International

NCT05701657

Recruiting 8,000 target

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

Stryker Instruments

NCT03072927

Recruiting Phase 3 8,000 target

Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial

The George Washington University Biostatistics Center

NCT06605118

Recruiting NA 7,500 target

Evaluating the Implementation and Impact of Navigator-delivered ePRO System

University of Alabama at Birmingham

NCT04809740

Recruiting 7,500 target

MYLUNG Consortium Part 3: Observational Study

US Oncology Research

NCT05885698

Recruiting NA 6,800 target

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

LivaNova

NCT03887715

Recruiting NA 6,618 target

Early Intervention to Promote Cardiovascular Health of Mothers and Children

JHSPH Center for Clinical Trials

NCT06272045

Recruiting 6,250 target

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

Eli Lilly and Company

NCT06566170

Recruiting NA 6,000 target

CGM for the Early Detection and Management of Hyperglycemia in Pregnancy

Jaeb Center for Health Research

NCT06957028

Recruiting 6,000 target

Histiocytic Disorder Follow-up Study

University of Alabama at Birmingham

NCT05915208

Recruiting Phase 3 6,000 target

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

Boehringer Ingelheim

NCT06424288

Recruiting Phase 4 6,000 target

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Duke University

NCT06909565

Recruiting Phase 3 6,000 target

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

Pfizer

NCT07160244

Recruiting Phase 3 5,951 target

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

NCT03959085

Recruiting Phase 3 5,600 target

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Novo Nordisk A/S

NCT05636176

Recruiting Phase 3 5,500 target

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

AstraZeneca

NCT05952557

Recruiting Phase 3 5,056 target

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Amgen

NCT07037459

Recruiting 5,000 target

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

National Cancer Institute LAO

NCT02474160

Recruiting Phase 3 5,000 target

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

AstraZeneca

NCT06283966

Recruiting 5,000 target

Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry

University of Alabama at Birmingham

NCT05556928

Recruiting Phase 2 5,000 target

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

QuantumLeap Healthcare Collaborative

NCT01042379

Recruiting 5,000 target

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

Prostate Cancer Clinical Trials Consortium

NCT03151629

Recruiting Phase 3 5,000 target

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

AstraZeneca

NCT06742723

Recruiting 5,000 target

TSC Biosample Repository and Natural History Database

National Tuberous Sclerosis Association

NCT05676099

Recruiting 5,000 target

Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset

The University of Texas Health Science Center, Houston

NCT05685745

Recruiting 5,000 target

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

Wake Forest University Health Sciences

NCT03615235

Recruiting 5,000 target

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Children's Oncology Group

NCT00736749

Recruiting Phase 3 4,800 target

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

AstraZeneca

NCT06307652

Recruiting 4,600 target

Risk Underlying Rural Areas Longitudinal Cohort Study (RURAL) Heart and Lung Study

The University of Texas Health Science Center at San Antonio

NCT05006729

Recruiting Phase 3 4,500 target

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Eli Lilly and Company

NCT07165028

Recruiting 4,500 target

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

Michael J. Fox Foundation for Parkinson's Research

NCT04477785

Recruiting 4,500 target

Investigations of Reproductive Cancers in Women

PinkDx

NCT06527157

Recruiting 4,490 target

Observational Study Protocol: LIVER-R

AstraZeneca

NCT06252753

Recruiting 4,400 target

Blue Light Cystoscopy With Cysview® Registry

Photocure

NCT02660645

Recruiting Phase 3 4,390 target

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Merck Sharp & Dohme

NCT07044297

Recruiting Phase 3 4,300 target

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

AstraZeneca

NCT05774951

Recruiting Phase 2 4,292 target

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

BioNTech SE

NCT05543616

Recruiting Phase 3 4,220 target

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Stemline Therapeutics

NCT06492616

Recruiting Phase 3 4,200 target

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

Boehringer Ingelheim

NCT06935370

Recruiting Phase 2 4,200 target

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

American Society of Clinical Oncology

NCT02693535

Recruiting NA 4,000 target

The Fourth Left Atrial Appendage Occlusion Study

Hamilton Health Sciences Corporation

NCT05963698

Recruiting 4,000 target

American Lung Association (ALA) Lung Health Cohort

Johns Hopkins University

NCT04543461

Recruiting Phase 3 4,000 target

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Vaxcyte

NCT07284654

Recruiting NA 4,000 target

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

University of British Columbia

NCT04634240

Recruiting Phase 3 3,960 target

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NRG Oncology

NCT05879926

Recruiting 3,784 target

Abbott Vascular Medical Device Registry

Abbott Medical Devices

NCT04573660

Recruiting Phase 3 3,680 target

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

National Cancer Institute (NCI)

NCT06058377

Recruiting 3,600 target

DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

George Washington University

NCT06525259

Recruiting 3,500 target

Lupus Landmark Study: A Prospective Registry and Biorepository

Lupus Research Alliance

NCT05934149

Recruiting Phase 3 3,082 target

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

Merck Sharp & Dohme

NCT06667700

Recruiting Phase 3 3,040 target

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Bristol-Myers Squibb

NCT07116967

Recruiting 3,000 target

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Duke University

NCT01915511

Recruiting 3,000 target

Rett Syndrome Registry

International Rett Syndrome Foundation

NCT05432349

Recruiting NA 2,998 target

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Melanoma and Skin Cancer Trials Limited

NCT03860883

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →